Current therapies for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis are limited by toxicity.

de Groot, K., Harper, L., Jayne, D., Flores Suarez, L., Gregorini, G., Gross, W., et al. (2009). Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial. ANNALS OF INTERNAL MEDICINE, 150(10), 670-680.

Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial

SINICO, RENATO ALBERTO;
2009

Abstract

Current therapies for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis are limited by toxicity.
Articolo in rivista - Articolo scientifico
Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Antineutrophil Cytoplasmic; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glomerulonephritis; Humans; Immunosuppressive Agents; Male; Middle Aged; Prednisolone; Pulse Therapy, Drug; Remission Induction; Treatment Outcome; Vasculitis; Young Adult
English
2009
150
10
670
680
none
de Groot, K., Harper, L., Jayne, D., Flores Suarez, L., Gregorini, G., Gross, W., et al. (2009). Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial. ANNALS OF INTERNAL MEDICINE, 150(10), 670-680.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/139366
Citazioni
  • Scopus 769
  • ???jsp.display-item.citation.isi??? 644
Social impact